FOLH1 Antibody | 18-999

FOLH1 Antibody | 18-999 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: N/A

Immunogen: A synthetic peptide of human FOLH1

Research Area: Cancer, Signal Transduction

Tested Application: WB, IHC, IF

Application: WB: 1:500 - 1:1000
IHC: 1:20 - 1:50
IF: 1:20 - 1:50

Specificiy: N/A

Positive Control 1: DU145

Positive Control 2: SKOV3

Positive Control 3: 293T

Positive Control 4: SGC-7901

Positive Control 5: HT-29

Positive Control 6: MCF7

Molecular Weight: Observed: 120kDa

Validation: N/A

Isoform: N/A

Purification: Affinity purification

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.02% sodium azide, pH7.3.

Concentration: N/A

Storage Condition: Store at 4˚C. Avoid freeze / thaw cycles.

Alternate Name: FOLH1, FGCP, FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA, mGCP

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: This gene encodes a type II transmembrane glycoprotein belonging to the M28 peptidase family. The protein acts as a glutamate carboxypeptidase on different alternative substrates, including the nutrient folate and the neuropeptide N-acetyl-l-aspartyl-l-glutamate and is expressed in a number of tissues such as prostate, central and peripheral nervous system and kidney. A mutation in this gene may be associated with impaired intestinal absorption of dietary folates, resulting in low blood folate levels and consequent hyperhomocysteinemia. Expression of this protein in the brain may be involved in a number of pathological conditions associated with glutamate excitotoxicity. In the prostate the protein is up-regulated in cancerous cells and is used as an effective diagnostic and prognostic indicator of prostate cancer. This gene likely arose from a duplication event of a nearby chromosomal region. Alternative splicing gives rise to multiple transcript variants encoding several different isoforms.